

APPLERA CORP  
Form 4  
November 03, 2005

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
WHITE TONY L

(Last) (First) (Middle)

APPLERA CORPORATION, 301  
MERRITT 7

(Street)

NORWALK, CT 06851-1070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
APPLERA CORP [ABI/CRA]

3. Date of Earliest Transaction  
(Month/Day/Year)

11/01/2005

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

Chairman, President and CEO

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3)       | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
| Applied Biosystems Group Common Stock | 11/01/2005                           |  | M                              | 12,585 A  | \$ 24.695 461,944.9951  | D  |   |
| Applied Biosystems Group Common Stock | 11/01/2005                           |  | D                              | 12,585 D  | \$ 24.695 449,359.9951  | D  |   |
| Applied Biosystems                    |                                      |  |                                |   | 75,000  | I  | By Elizabeth  |

|   |   |  |
|---|---|--|
| Group<br>Common<br>Stock<br><br><br><br><br><br><br><br><br><br>Applied<br>Biosystems<br>Group<br>Common<br>Stock | 48,480<br><br><br><br><br><br><br><br><br><br>I | Ann<br>White<br>Business<br>Interests,<br>LLLP <sup>(2)</sup><br><br>By Tony<br>Lee<br>White<br>2004 Two<br>Year<br>Grantor<br>Retained<br>Annuity<br>Trust <sup>(3)</sup> |
|---|---|--|

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3)               | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable      Expiration Date                    | Title   |
| Applied Biosystems Group Series FY03-3 Performance Units | \$ 0 <sup>(4)</sup>                                    | 11/01/2005                           |  | M                              | 20,000 <sup>(5)</sup>   | <sup>(4)</sup> 03/24/2013                                | Applied Biosystems Group Common Stock <sup>(4)</sup>          |

## Reporting Owners

| Reporting Owner Name / Address      | Relationships |           |                             |       |
|-------------------------------------|---------------|-----------|-----------------------------|-------|
|                                     | Director      | 10% Owner | Officer                     | Other |
| WHITE TONY L<br>APPLERA CORPORATION | X             |           | Chairman, President and CEO |       |

301 MERRITT 7  
NORWALK, CT 06851-1070

## Signatures

/s/ Thomas P. Livingston, Attorney-In-Fact for Tony L.  
White

11/03/2005

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents settlement of Performance Units for cash as described in footnote 5 below. Price listed is the fair market value of Applera Corporation - Applied Biosystems Group Common Stock ("ABI Stock") on the settlement date.  
  
Elizabeth Ann White Business Interests, LLLP, is a family limited partnership (the "FLP"). The reporting person's daughter is the sole
- (2) general partner of the FLP, and the reporting person's wife and a grantor retained annuity trust established by the reporting person are currently the sole limited partners of the FLP.
- (3) The reporting person's wife is the sole trustee of the Tony Lee White 2004 Two Year Grantor Retained Annuity Trust.  
  
The Performance Units provide for payment upon ABI Stock attaining price targets of \$18.54 and \$22.29 per share for a specified period
- (4) and are payable over a minimum of eight quarters, subject to continued employment and an aggregate program expense cap. Units are payable in cash equal to \$15.54 for each Performance Unit.
- (5) Represents the payment of 20,000 Performance Units upon attainment of the \$22.29 price target described in footnote 4 above.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.